PN-2034(PN-2034) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

PN 2034、PN2034、SAR-176975

靶点-

作用机制

胰岛素增敏剂

治疗领域

内分泌与代谢疾病

在研适应症-

非在研适应症

2型糖尿病

原研机构

Wellstat Therapeutics Corp.

在研机构-

非在研机构

Wellstat Therapeutics Corp.

Sanofi

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 PN-2034 相关的临床试验

NCT00110864 / Completed临床2期

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes

This study is designed to evaluate the safety and efficacy of PN2034 in insulin-dependent type 2 diabetics as measured by the change in average daily insulin dose from baseline to week 12. The effects of PN2034 on HbA1c, fasting plasma glucose (FPG), and lipid levels will also be measured.

开始日期2005-05-01

申办/合作机构

Wellstat Therapeutics Corp.

NCT00110851 / Completed临床2期

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Effects of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet) Therapy

This study is designed to evaluate the safety and efficacy of PN2034 administered to type 2 diabetics on concomitant rosiglitazone and metformin (or Avandamet) therapy as measured by change in glycosylated hemoglobin (HbA1c) levels from baseline to Week 12. Also the study will evaluate the effect of PN2034 on glucose control as measured by fasting plasma glucose (FPG) and on fasting lipid levels: triglycerides, total cholesterol, high-density lipoproteins (HDL), low-density lipoproteins (LDL), and very low-density lipoproteins (VLDL).

开始日期2005-04-01

申办/合作机构

Wellstat Therapeutics Corp.

100 项与 PN-2034 相关的临床结果

登录后查看更多信息

100 项与 PN-2034 相关的转化医学

登录后查看更多信息

100 项与 PN-2034 相关的专利（医药）

登录后查看更多信息

100 项与 PN-2034 相关的药物交易

登录后查看更多信息